Jasper Therapeutics, Inc. - Class A Common Stock JSPR 深 沪
已收盘 08-22 16:00:00 美东时间
2.93
-0.020
-0.68%
华盛通- 最 高3.05
- 今 开2.96
- 成交量 17.27万股
- 最 低 2.93
- 昨 收 2.95
- 总市值 4762.22万
- 52周最高 26.05
- 市盈率 静 --
- 换手率 1.06%
- 52周最低 2.265
- 委 比 -34.53%
- 总股本 1625.33万
- 历史最高 188.80
- 量 比 0.83
- 振 幅 4.07%
- 历史最低 2.265
- 每 手 1
- 风险率 7.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多UBS Maintains Buy on Jasper Therapeutics, Lowers Price Target to $25
UBS analyst Trung Huynh maintains Jasper Therapeutics (NASDAQ:JSPR) with a Buy and lowers the price target from $29 to $25.
08-15 22:21
Jasper Therapeutics Q2 EPS $(1.74) Misses $(1.40) Estimate
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.74) per share which missed the analyst consensus estimate of $(1.40) by 24.55 percent. This is a 79.38 percent decrease over losses of $(0.97) per share
08-14 04:26
Jasper Therapeutics Announces Major Corporate Reorganization
Jasper Therapeutics ( ($JSPR) ) has provided an update. On July 8, 2025, Jasper...
07-09 20:29
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway
Jasper Therapeutics announced a corporate reorganization to extend its cash runway, including a workforce reduction of approximately 50%. Dr. Edwin Tucker is departing as Chief Medical Officer, and Dr. Daniel Adelman will serve as Acting Chief Medical Officer. The company is focusing on its briquilimab programs in chronic urticaria and halting other clinical and preclinical programs.
07-09 12:00
美股大行评级 | 潜在涨幅687%！ 花旗上调新氧科技目标价升至5.5美元，评级"买入"
今日重点评级关注：B. Riley证券：维持内克塔治疗"买入"评级，目标价从60美元升至85美元；Oppenheimer：维持Praxis Precision Medicine"跑赢大市"评级，目标价从97美元升至115美元
07-09 09:26
美股大行评级 | 潜在涨幅199.47%！杰富瑞上调Cogent Biosciences目标价至28美元，维持"买入"评级
今日重点评级关注：杰富瑞：维持Cogent Biosciences"买入"评级，目标价从23美元升至28美元；Leerink Partners：维持Cogent Biosciences"跑赢大市"评级，目标价从16美元升至18美元
07-08 09:34
William Blair Downgrades Jasper Therapeutics to Market Perform
William Blair analyst Matt Phipps downgrades Jasper Therapeutics (NASDAQ:JSPR) from Outperform to Market Perform.
07-08 05:20
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 171.6% to $27....
07-07 20:07
Jasper Therapeutics Reports Promising Briquilimab Study Results
Jasper Therapeutics ( ($JSPR) ) has provided an update. On July 7, 2025, Jasper...
07-07 19:55
Jasper Reports 89% Response Rate in Urticaria Study, Halts Asthma Program After Drug Lot Issue
Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as
07-07 19:33
